Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-19 Sale | 2024-03-21 4:37 pm | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 12,795 | $2.0855 | $26,684 | 168,579 (Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:14 pm | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 4,077 | $1.3805 | $5,628 | 155,124 (Direct) | View |
| 2023-09-22 Sale | 2023-09-22 7:16 pm | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 4,119 | $1.3003 | $5,356 | 147,951 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-01-18 Option Award | 2024-01-19 8:38 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 223,750 | $0 | 378,874 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:54 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 11,250 | $0 | 170,451 (Direct) | View |
| 2023-09-20 Option Award | 2023-09-22 7:16 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 11,250 | $0 | 147,951 (Direct) | View |
| 2023-03-22 Option Award | 2023-03-29 7:54 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 60,000 | $0 | 140,820 (Direct) | View |
Ownership | 2023-03-29 7:50 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 0 | $0 | 881,310 (Direct) | View |